0
Article ? AI-assigned paper type based on the abstract. Classification may not be perfect — flag errors using the feedback button. Tier 2 ? Original research — experimental, observational, or case-control study. Direct primary evidence. Environmental Sources Human Health Effects Policy & Risk Sign in to save

Microplastic particles and infusion therapy — Evidence, implications, and unanswered questions

Journal of Hazardous Materials Advances 2026 Score: 50 ? 0–100 AI score estimating relevance to the microplastics field. Papers below 30 are filtered from public browse.
Leonard Saur, Marc von Pawlowski, Marc von Pawlowski, Marc von Pawlowski, Leonard Saur, Leonard Saur, Leonard Saur, Jochen Röthele, Jochen Röthele, Jochen Röthele, Christian Pylatiuk, Christian Pylatiuk, Christian Pylatiuk Christian Pylatiuk Christian Pylatiuk

Summary

This review highlights infusion therapy via medical devices and pharmaceutical containers as a significant but often overlooked route of microplastic exposure in humans. The study emphasizes that despite strict regulations, advances in clinical research have not been fully integrated into current industry testing standards, and calls for a standardized, multi-method approach to microplastic detection and risk assessment in medical settings.

• Infusion therapy identified as significant, overlooked microplastic exposure route • Review emphasizes clinical relevance of particle properties beyond size • Addresses limitations of current test methods and regulatory standards for microplastics • Proposes functional classification of particles based on size for clinical relevance • Calls for standardized, multi-method approach for microplastic detection and risk assessment The growing accumulation of plastic waste, including microscopic particles in the environment, is an alarming development. It has long been recognised that these particles can enter the human body. Recent studies focus on environmental sources of these particles. This article highlights a less frequently discussed, but significant, route of exposure: the infusion of particles via medical devices and pharmaceutical containers. One possible reason for this is the assumption that infusion devices are inherently safe due to strict regulations and rigorous testing. Nonetheless, advances in clinical research and the development of specialised test methods have yet to be fully integrated into current industry standards. This paper reviews the current understanding of microscopic plastic particles, with emphasis on their interaction with the human body, applied test methods and limitations. It further contrasts these insights with existing regulations. Finally, it identifies key areas for future interdisciplinary research in biomedicine, engineering, and public health.

Sign in to start a discussion.

Share this paper